中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 2
Feb.  2020
Turn off MathJax
Article Contents

Downstaging and conversion treatment of intermediate and advanced liver cancer should be taken seriously

DOI: 10.3969/j.issn.1001-5256.2020.02.001
  • Received Date: 2020-01-07
  • Published Date: 2020-02-20
  • Surgical treatment is the most effective approach to achieving radical treatment and long-term survival of liver cancer. At present,most patients with intermediate and advanced liver cancer do not have the opportunity to receive radical surgery. The downstaging and conversion treatment strategies for intermediate and advanced liver cancer should be taken seriously in clinical practice to further improve treatment outcome. According to disease stage and conditions of patients with intermediate and advanced liver failure,multidisciplinary cooperation is needed to optimize downstaging and conversion treatment regimens,which may help inoperable patients to obtain the opportunity for surgical treatment. Palliative therapy can be changed to radical surgical resection,and patients who cannot undergo antitumor treatment can still receive palliative therapy. More patients with intermediate and advanced liver cancer are able to achieve a better clinical outcome,an improvement in prognosis,and long-term survival.

     

  • loading
  • [1] ZHENG RS,SUN KX,ZHANG SW,et al. Report of cancer epidemiology in China,2015[J]. Chin J Oncol,2019,41(1):19-28.(in Chinese)郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
    [2] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
    [3] LLOVET JM,MONTAL R,SIA D,et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol,2018,15(10):599-616.
    [4] VILLANUEVA A. Hepatocellular carcinoma[J]. New Engl J Med,2019,380(15):1450-1462.
    [5] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范(2017年版)[J].临床肝胆病杂志,2017,33(8):1419-1431.
    [6] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36(2):277-292.
    [7] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.
    [8] MARRERO JA,KULIK LM,SIRLIN CB,et al. Diagnosis,staging, and management of hepatocellular carcinoma:2018practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2018,68(2):723-750.
    [9] VOGEL A,CERVANTES A,CHAU I,et al. Hepatocellular carcinoma:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2018,29(Suppl 4):iv238-iv255.
    [10] WEI X,JIANG Y,ZHANG X,et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1517) PDF downloads(393) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return